Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XELOX vs FOLFOX-4 with or without Bevacizumab in mCRC
NCT00069095Phase 3Completed
- Sponsor
- Roche
- Start
- Jul 2003
- Primary completion
- Jan 2006
- Modality
- Monoclonal Antibodies
- Countries
- 33
01
Overview
A Phase 3 trial of bevacizumab in colorectal cancer (metastatic) (mCRC), sponsored by Roche. Started Jul 2003; status: completed.
02
Drugs
bevacizumab
03
Conditions
colorectal cancer (metastatic) (mCRC)
Beyond the preview
Go deeper on NCT00069095.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00069095.